Navigation Links
NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
Date:4/15/2009

ANDREW L. PECORA, MD, FACP, CPE TO JOIN NEOSTEM'S ADVISORY BOARD

NEW YORK, April 15 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, today announced that it will be moving its commercial adult stem cells processing and storage operations and utilizing exclusively Progenitor Cell Therapy, LLC (PCT), a leading international provider of cGMP cell therapy manufacturing and storage. In addition, Andrew L. Pecora, MD, FACP, CPE, who is Chairman and CEO of PCT, has agreed to join NeoStem's Advisory Board to work more closely with the company for future endeavors overseas.

Progenitor Cell Therapy is a client-based cell therapy services company that supports the development and commercialization of cellular therapies by providing current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing and eventual commercialization of cellular therapies for clients throughout the world. This relationship will allow NeoStem to utilize the highest cGMP standard within the industry and associate itself further with clinicians, scientists, and business executives with significant accomplishments in both the general field of health care and specifically within the field of cell-based therapeutics.

NeoStem and PCT believe that cGMP-compliant adult stem cell blood banking will be essential for the use of these stem cells in many of the more complex future therapies presently being developed. PCT, which has extensive experience in adult stem cell and cord blood processing, storage and distribution for clinical use, is one of the few multiple-cell therapy manufacturing facilities in the world to process and store cells in compliance with the FDA's cGMP standards.

In commenting about the potential relationship, Dr. Robin Smith, CEO, NeoStem, stated, "This relationship between our two companies is both exciting and another example of our drive to develop best practices for our growing clientele, including those worldwide as we expand our activities outside of the United States. In addition, we are thrilled that Andrew Pecora, MD, FACP. has agreed to join our prestigious board of advisors. His medical expertise and practical business experience fit well with the very distinguished medical leaders who have already joined our board."

Dr. Andrew L. Pecora, said, "PCT is very pleased to establish this strategic business alliance with NeoStem. NeoStem has a growing list of alliances with important enterprises developing in this very exciting adult stem cell medical field. We believe PCT's cGMP standards will enhance the high-quality services NeoStem provides and give it a competitive advantage for the future. Moreover, NeoStem's VSEL stem cell technology holds great promise for future innovations for which PCT can provide critical support. I look forward to working with Dr. Smith and her team."

About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells that are found in your body), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

About Progenitor Cell Therapy, LLC

Progenitor Cell Therapy (PCT) is a client-based services company that supports the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include whether there is consumer acceptance of stem cell therapies, whether the VSEL technology leads to marketable therapeutic products and those set forth under 'Risk Factors" described in the Company's Annual Report on Form 10-K for its fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission.

    Contact:
    NeoStem, Inc.
    Robin Smith, Chief Executive Officer
    T: 212-584-4180
    Email: rsmith@neostem.com
   http://www.neostem.com/


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
2. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
3. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):